Initial comments on abstracts for the GU Oncology meeting

So while there are a lot of prostate cancer-specific data being presented at the upcoming Genitourinary Oncology meeting in  San Francisco, several of the apparently important presentations are actually not “new” because they have already been presented elsewhere. For example:

  • A presentation by Lee et al. (abstract no. 1; “NRG Oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer”) was already given at the ASTRO meeting in late 2015 and was summarized here by Allen Edel on The “New” Prostate Cancer InfoLink.
  • A presentation by Dearnaley et al. (abstract no. 2; “Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: results from the phase III randomized CHHiP trial (CRUK/06/016)”) was previously given at the European Cancer Congress in late 2015 and was summarized here (again by Allen Edel) on The “New” Prostate Cancer InfoLink.
  • A presentation by Shipley et al. (abstract no. 3; “NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA”) was also first given at ASTRO last year and was summarized by Allen Edel in this post.

There are, however, other new data from a range of radiation therapy studies, and Allen will be commenting on these over the next week or so.

The most interesting “new” information that we have spotted so far are data from the STAMPEDE trial suggestive (perhaps unexpectedly) of a survival benefit among men with metastaic prostate cancer treated with standard of care + celecoxib (a COX-2 inhibitor) + zoledronic acid compared to standard of care alone. We have addressed this in a separate post this morning.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: